Areas of Focus
- Pharmaceutics
- Nanomedicine
Work Experience
- 2022 - present: Researcher, Peking University School of Pharmaceutical Sciences
- 2019.5-2022.3: Senior Researcher, Gilead Sciences Formulation Development Department
- 2018.10-2019.5: ORISE Fellow, US FDA
- 2016.8-2019.5: Postdoctoral Researcher, Koch Institute for Integrative Cancer Research, MIT
Academic Background & Achievements
- 2022 - present: Researcher, Peking University School of Pharmaceutical Sciences
- 2012.8-2016.5: Ph.D. in Science, University of North Carolina at Chapel Hill
- 2008.9-2012.7: B.Sc. in Science, Shandong University School of Pharmacy
Publications
- Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver, Miao L., Lin J., Huang Y., Li L., Delcassian D., Ge Y., Shi Y., Anderson D.G., 2020
- Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation, Miao L., Li L., Huang Y., Delcassian D., Chahal J., Han J., Shi Y., Sadtler K., Gao W., Lin J., Doloff J.C., Langer R., Anderson D.G., 2019
- Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic cancer, Miao L., Li J., Liu Q., Feng R., Das M., Lin C.M., Goodwin T.J., Dorosheva O., Liu R., Huang L., 2017
- Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy, Lu X., Miao L., Gao W., Chen Z., McHugh K.J., Sun Y., Tochka Z., Tomasic S., Sadtler K., Hyacinthe A., Huang Y., Graf T., Hu Q., Sarmadi M., Langer R., Anderson D.G., Jaklenec A., 2020
- Targeting tumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors, Miao L., Liu Q., Lin C.M., Luo C., Wang Y., Liu L., Yin W., Hu S., Kim W.Y., Huang L., 2017